Data analysis revealed: Zhejiang Province bidding smoke four!

Source: Xianda data 2015-3-25 first, review the basic information of the first and second batch of procurement in Zhejiang The first batch of procurement scope "includes the national essential drug catalog (2012) Edition) and the list of commonly used drugs out of the basic drug list of basic medical and health institutions in Zhejiang Province (tentative), the list of low-cost drugs centralized procurement in Zhejiang Province (I), and the list of drugs in short clinical supply in Zhejiang Province All drugs belonging to the catalogue of basic drugs and Zhejiang Province low price Drugs centralized purchase catalogue (I), other dosage forms, specifications and different acid roots or bases under the same general name are also included in the scope of this centralized purchase The second batch of procurement mainly covers "products (including low-cost drugs) that are currently traded online on the provincial procurement platform and have distribution records during the period from January 1, 2013 to December 31, 2014, excluding products without distribution records during the period and products with the same generic name in the 2014 centralized procurement (first batch) procurement catalogue of drugs in Zhejiang Province and drugs for record" 。 That is to say, the first batch of drugs purchased is mainly for primary medical use, and the second batch of drugs purchased is mainly for sale in Zhejiang Province The first and second batch of purchasing medical institutions are "all the grass-roots medical and health institutions implementing the national basic drug system in Zhejiang Province, the secondary and higher level medical institutions run by the health administrative department of the people's government at or above the county level, the non-profit medical institutions run by other departments, institutions and state-owned (including state-owned holding) enterprises of the people's government at or above the county level" This indicates that the medical institutions targeted by the two bids include hospitals at the grass-roots level and above the county level According to the monitoring of Xianda bidding data monitoring system on the procurement platform of Zhejiang Pharmaceutical machinery, as shown in Table 1-1, according to the statistics of product names, the winning rate of the first batch of products (except for the procurement catalogue of drugs with limited clinical supply) is 54.8%, of which the winning rate of low-cost drugs is 60.8%, and the winning rate of general infusion is 75.0% The bid winning rate of other product catalogues (including the national basic drug purchase catalogue and the list of commonly used drugs out of the basic drug catalogue, the same below) is 52.1% The proposed bid winning rate of the second batch of product catalog is 69.1% If calculated according to the product specifications, as shown in table 1-2, the bid winning rate of the first batch of products (except for the purchase catalogue of drugs with limited clinical supply) is 56.8%, of which the bid winning rate of low-cost drugs is 65.9%, and the bid winning rate of ordinary infusion is 31.2% The proposed winning rate of other product catalogue is 52.8% The proposed bid winning rate of the second batch of product catalog is 67.5% According to the statistics, the bid winning results of the manufacturers corresponding to the drug product specifications are shown in table 1-3 The proposed bid winning rate of the manufacturers of the second batch of product specifications is 67.0% From the data point of view, the two batches of bid winning situation is almost the same, the second batch of bid winning rate is higher than the first batch of bid winning rate, that is to say, the current situation of non essential drugs in Zhejiang is better than that of drugs used in primary medical treatment 67% of the second batch of drugs to be awarded the bid Since the second batch of drugs to be purchased are mainly drugs on sale in Zhejiang Province, 67.0% of the second batch of products are to be awarded by the manufacturer of product specifications, which means that 33% of the target drugs to be sold have abandoned the bid Why do so many products prefer to lose the market cultivated since 2010 to keep the price? In 2014, the product catalog (public draft) of Zhejiang drug centralized purchase (the second batch) had 5202 numbers of products to be purchased, of which 3497 were not included in the price sorting rules for bidding products of Zhejiang drug centralized purchase (the second batch) in 2014 (zdpf [2015] 6) (No.) in the information table of combing results of price (decrease) of two bidding products, of 3497 drug serial numbers that are not recorded, 3488 are to be awarded, and 9 are not to be awarded According to Xianda bidding data monitoring system, of the 1705 drug serial numbers in the two bidding product price (reduction) combing result information tables, only 5 are to win the bid, and 1700 are not to win the bid, that is to say, the drug serial numbers of the final unsuccessful products are mainly the products in the two bidding product price (reduction) combing result information tables It is worth noting that the price reduction rate of the five products to be awarded is more than 10% One of the five data to be awarded belongs to foreign enterprises / joint ventures, and four belong to domestic enterprises Why do the products that enter into the price (reduction) of two bidding products sort out the result information table abandon the bidding so much? According to the implementation plan of 2014 drug centralized procurement (the second batch) in Zhejiang Province and the notice on Issuing the price sorting rules for bidding products of 2014 drug centralized procurement (the second batch), the second batch of bidding is carried out in the way of determining the price, which means that the price of Online transactions in the purchasing platform of Zhejiang Province has dropped by 10% Among them, for those belonging to traditional Chinese medicine injection or antibacterial drugs, the reference price will be reduced by 5% on the basis of 10%; for those belonging to the top 200 varieties of distribution amount published by our province in 2013, on the basis of 10%, the top 50 varieties will be reduced by 5%, 51-100 varieties will be reduced by 4%, 101-150 varieties will be reduced by 3%, 151-200 varieties will be reduced by 2% At the same time, according to the above two cases, the reduction accumulation calculation Prices not confirmed before February 28, Zhejiang Province publicized in the information table of two bidding product prices (reduction), that is to say, drug serial numbers not in the information table all correspond to the price reduction logic, and 67% of the enterprises corresponding to drug serial numbers accepted the price reduction The "reduced" enterprises in the information table express that they can't hold the latest price reduction in Zhejiang with practical actions In addition, Zhejiang "establishes a price linkage mechanism", and Zhejiang price is linked with the lowest price in China (excluding Guangdong, Fujian and the military region) What is the winning rate of 44% bid abandonment / joint venture of foreign enterprises? According to the data observed by Xianda bidding data monitoring system, as shown in Table 2, the number of domestic products accounts for 88% of the total number of catalogue products, and the number of foreign enterprises / joint ventures accounts for 12% 44% of the number of imported / joint venture products won the bid, slightly higher than 31% of domestic enterprises Among the 1841 enterprises corresponding to 5202 product numbers, 364 enterprises abandoned the standard 100%, such as Tianbian pharmaceutical, Beijing Taide and Zhejiang Meiwu, etc The Xianda bidding data monitoring system found that the price reduction range of the two bidding products was between 5% and 19%, among which the three main peaks were (1) 10%, corresponding to 1280 drug serial numbers; (2) 5%, corresponding to 184 drug serial numbers; (3) 14.5%, corresponding to 114 drug serial numbers (see Figure 1) There are two products with 19% reduction, namely, moxifloxacin hydrochloride sodium chloride injection of Bayer and Xiyanping injection of Jiangxi Qingfeng There are 1705 drug serial numbers in the information table of combing the price (decrease) of two bidding products, which belong to 907 enterprises respectively According to the statistics of drug serial numbers, the domestic enterprise with the largest number of drug serial numbers is Shanghai Yunjia Huangpu Pharmaceutical Co., Ltd., with a total of 17 In the information table, the related products are mainly external drugs, followed by Jiangxi tianshikang traditional Chinese Medicine Co., Ltd and Sichuan Kelun Pharmaceutical Co., Ltd., with 13 drug serial numbers in the information table Bayer is the foreign company with the largest number of products failed to win the bid due to entering the information table, and a total of 16 drug serial numbers failed to win the bid There are 1327 products corresponding to 1705 drug serial numbers In the information table, the product with the largest number of drug serial numbers is ornidazole sodium chloride injection, with a total of 9 serial numbers affected, followed by recombinant human granulocyte stimulating factor injection, with a total of 8 serial numbers affected 363 of 907 enterprises have their product serial numbers in the information table To sum up, the bid abandonment rate of the second batch of foreign enterprises bidding in Zhejiang is slightly higher, but it does not reach the level of 60% of foreign enterprises bidding abandonment Among the 1841 enterprises, 472 enterprises, 25.6% of which have the corresponding product rejection rate higher than 60% (including 60%) There are many foreign enterprises in the list of 472 enterprises, such as Xi'an YANGSEN, Bayer, Wyeth, etc similarly, there are many domestic enterprises in the list of 472 enterprises, such as Shandong LVYE, Guangdong techpool biochemical, etc Willing to lose or let go? In my opinion, the main reason for the bid abandonment rate is that Zhejiang has directly come to a current platform to reduce the sales of products by 10% and then the top enterprises need to reduce the price again and again All enterprises do not agree with this logic of price reduction In terms of the final result, 67% of the products and regulations enterprises finally recognized it, which gave a signal to the government that the provincial-level one-time in place pricing scheme was feasible For enterprises, whether to give up the regional market or the price, the second batch of Zhejiang bidding has given us an answer Some enterprises prefer to choose the price to protect most regional markets Only in the next year's review can we know whether this protection is right when we abandon small areas and finally find no areas to give up in the big melody of price reduction; or if we want to gamble and lose as early as possible, we need to re plan the marketing strategy layout from the cost, and change the existing high cost model of the product to cope with the big environment is a better choice No matter what choice you make, you are betting on the future The industry is shuffling I wish you all well.